课题基金 / 基金详情

CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)

CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)
临床试验：合作亨廷顿氏观察试验（队列）
批准号：
7950967
负责人：
JODY COREY-BLOOM
金额：
$1.98万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
项目状态：
已结题
起止时间：
2008-12-01 至 2009-11-30
来源：
https://reporter.nih.gov/project-details/7950967
关键词：
Clinical ResearchClinical TrialsComputer Retrieval of Information on Scientific Projects DatabaseDataDiseaseFamilyFundingFutureGrantIndividualInstitutionLearningOther GeneticsPharmaceutical PreparationsPhenotypeResearchResearch PersonnelResourcesSourceUnited States National Institutes of Healthprospectiveresearch study

项目摘要

项目成果

JODY COREY-BLOOM的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 收集来自HD家庭成员的预期数据，将个人和家庭之间的表型彼此之间以及遗传因素联系起来，以便更多地了解HD，开发潜在的疾病治疗方法，并计划未来旨在减缓或推迟HD进展的实验药物的研究。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Collect prospective data from individuals who are part of an HD family, relating phenotypes between individuals and families with each other and genetic factors, in order to learn more about HD, develop potential treatments for the disease, and plan for future research studies of experimental drugs aimed at slowing or postponing the onset of progression of HD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FRONTOSTRIATAL ACTIVATION IN SUBJECTS AT RISK FOR HUNTINGTON'S DISEASE
CLINICAL TRIAL: ACR16 VERSUS PLACEBO FOR THE SYMPTOMATIC TREATMENT OF HUNTINGTON
CLINICAL TRIAL: PHASE 3 STUDY OF DIMEBON IN PATIENTS WITH MILD-TO-MODERATE HUNTI
CLINICAL TRIAL: COOPERATIVE HUNTINGTON'S OBSERVATIONAL TRIAL (COHORT)
海外基金